A review of the efficacy and safety of extended-release topiramate in the adjunctive treatment for refractory partial-onset seizures.
Topiramate has been widely utilized worldwide as an effective medication against partial- and generalized-onset seizures. Extended-release topiramate was developed to provide patients with the convenience of once-daily dosing and potentially improved tolerability by reducing serum concentration fluctuation. USL255 is a once-daily, extended-release formulation of topiramate, which was recently approved in the USA. Compared with immediate-release topiramate taken twice daily, once-daily USL255 provides equivalent topiramate exposure with a 26% reduction in plasma fluctuations. A multinational, phase III, randomized, double-blind, placebo-controlled clinical trial in patients with refractory partial-onset seizures demonstrated that USL255 (200 mg/day) significantly improved seizure control and was well tolerated with low overall neuropsychiatric and neurocognitive adverse events.
Department of Neurology, Barrow Neurological Institute, Banner University Medical Center 500 West Thomas Road Suite 300, Phoenix, AZ 85013, USA.
Steve S
SS
Chung
epilepsy; extended release; partial seizures; qudexy XR; topiramate; trokendi XR